SCOPE 2026

R&D

SCOPE 2026 was dominated by one big topic: AI. You couldn’t walk five steps without hearing about something that AI was going to fix.

News

Ipsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.